Igenomix USA

Igenomix USA

Igenomix USA operates out of Miami, Florida, as part of a broader international network of genetic testing laboratories. The parent entity, Igenomix, was founded in 2011 in Spain by Dr. Carlos Simón, a leading figure in reproductive medicine, and has expanded to over 20 countries. The US arm provides preimplantation genetic testing (PGT) services, including aneuploidy screening, monogenic disorder detection, and chromosomal structural rearrangement analysis, to fertility clinics and academic institutions. The firm's core business involves genetic analysis of embryos and reproductive health diagnostics, serving the assisted reproductive technology (ART) sector. It does not publicly disclose deployment figures, investment strategies, or asset class allocations, as its operations are service-based rather than capital deployment. The firm's geographic footprint includes the US market, with additional labs in Europe, Latin America, and Asia forming a global network. No recent operational events are publicly verifiable for Igenomix USA as of mid-2026. The firm does not report AUM, team size, or professional staff publicly. It operates without disclosed philanthropic or adjacent investment vehicles, and its structure appears as a limited liability company subsidiary within the broader Igenomix corporate structure. Igenomix USA's structural differentiator is its role as a service provider in a specialized medical niche, rather than a capital allocator. It generates revenue through laboratory testing fees, not investment returns. This operational model distinguishes it from family offices or asset managers, and its primary competitive moat lies in the intellectual property and regulatory approvals held by its parent group in reproductive genetics.